The U.S. Food and Drug Administration said on Monday it had approved Global Blood Therapeutics’s drug, Oxbryta, to treat sickle cell disease in adults and pediatric patients aged 12 years or older. The disease is a lifelong, inherited blood disorder in which abnormally shaped red blood cells restrict flow of blood in vessels, leading to severe pain and organ damage. The drug, also known as voxelotor, aims to treat the underlying cause of sickle cell disease by preventing sickle cells from deforming. …read more
Source:: Yahoo Finance
